8-K filing — PULSE BIOSCIENCES, INC. (PLSE)
Filed: 2026-10-14 AccNo: 0001437749-26-032601 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.
Pulse Biosciences Announces Completion Of 164-Patient Enrollment In Pivotal Atrial Fibrillation Study Of nPulse Catheter, Three Months Ahead Of Schedule